Journalartikel

Jahr der Veröffentlichung: 2015

Seiten: 307-314

Zeitschrift: Der Internist

Bandnummer: 56

Heftnummer: 3

ISSN: 0020-9554

eISSN: 1432-1289

DOI Link: https://doi.org/10.1007/s00108-014-3651-2

Verlag: Springer

Abstract: 
The term modern disease-modifying antirheumatic drugs (DMARD) includes not only the constantly growing family of DMARDs for chronic inflammatory rheumatic diseases but also the repositioning of established drugs in updated and novel algorithms of the different entities. The usual precursor for these developments is rheumatoid arthritis for which completely revised and updated guidelines have been published not only in Germany but also on the European level. In addition, label extensions to existing drugs have been granted for connective tissue diseases and vasculitides, e.g. anti-CD20 antibodies for antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides and belimumab for systemic lupus erythematosus. Moreover, several novel drugs, especially of the biologics class, have been either introduced in clinical rheumatology or are close to being licensed and include ustekinumab for psoriatic arthritis, granulocyte growth inhibitors and janus kinase inhibitors for rheumatoid arthritis and atacicept for systemic lupus erythematosus. With the termination of the patent for several biologics, a new momentum also took place: the approval of the so-called biosimilars which has already initiated intensive discussions not only with respect to "similar" effects and side effects but also with respect to their potential impact on economical aspects.

Harvard-Zitierstil: Mueller-Ladner, U., Richter, K. and Tarner, I. (2015) Modern disease-modifying antirheumatic drugs, Der Internist, 56(3), pp. 307-314. https://doi.org/10.1007/s00108-014-3651-2

APA-Zitierstil: Mueller-Ladner, U., Richter, K., & Tarner, I. (2015). Modern disease-modifying antirheumatic drugs. Der Internist. 56(3), 307-314. https://doi.org/10.1007/s00108-014-3651-2